Premium
Pro32Thr Polymorphism of Inosine Triphosphate Pyrophosphatase Gene Predicts Efficacy of Low‐Dose Azathioprine for Patients With Systemic Lupus Erythematosus
Author(s) -
Okada Y,
Nakamura K,
Hiromura K,
Nojima Y,
Horiuchi R,
Yamamoto K
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.261
Subject(s) - itpa , pyrophosphatase , azathioprine , medicine , pharmacology , single nucleotide polymorphism , gene polymorphism , polymorphism (computer science) , systemic lupus erythematosus , immunology , gastroenterology , gene , biology , disease , allele , genotype , biochemistry , enzyme , virus , hepatitis c virus , ribavirin
We evaluated the relationship between the efficacy of low‐dose azathioprine (AZA) therapy and the inosine triphosphate pyrophosphatase ( ITPA ) 94C>A (Pro32Thr) polymorphism in patients with systemic lupus erythematosus (SLE). We performed a multiple regression analysis to assess the influence of various factors on the reduction in SLE disease activity index (SLEDAI) scores. The ITPA 94C>A polymorphism had the highest correlation with the change in SLEDAI score ( r = 0.354, P = 0.006). Clinical Pharmacology & Therapeutics (2009); 85 , 5, 527–530 doi: 10.1038/clpt.2008.261